v3.25.3
Consolidated Statements of Shareholders' Equity (Deficit) (unaudited) - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-in Capital
Accumulated Deficit
Accumulated Other Comprehensive Income (Loss)
Beginning balance (in shares) at Dec. 31, 2023   147,978,000      
Beginning balance at Dec. 31, 2023 $ (331,923) $ 1,480 $ 3,113,487 $ (3,446,145) $ (745)
Comprehensive loss:          
Net loss (678,224)     (678,224)  
Other comprehensive income 1,292       1,292
Exercise of stock options and ESPP share issuance (in shares)   4,498,000      
Exercise of stock options and ESPP share issuance 99,503 $ 45 99,458    
Net proceeds/payments from issuance of common stock (in shares)   19,537,000      
Net proceeds/payments from issuance of common stock 1,084,136 $ 195 1,083,941    
Issuance of common stock for vesting of RSUs (in shares)   896,000      
Issuance of common stock for vesting of RSUs 9 $ 9      
Deferred payments for Business Acquisition and Vertuis Bio, Inc. (in shares)   197,000      
Deferred payments for Business Acquisition and Vertuis Bio, Inc. 14,082 $ 2 14,080    
Issuance of common stock upon conversion of convertible notes (in shares)   5,741,000      
Issuance of common stock upon conversion of convertible notes 224,259 $ 57 224,202    
Stock-based compensation expense 70,281   70,281    
Ending balance (in shares) at Sep. 30, 2024   178,847,000      
Ending balance at Sep. 30, 2024 483,415 $ 1,788 4,605,449 (4,124,369) 547
Beginning balance (in shares) at Jun. 30, 2024   166,667,000      
Beginning balance at Jun. 30, 2024 38,818 $ 1,667 3,943,826 (3,903,845) (2,830)
Comprehensive loss:          
Net loss (220,524)     (220,524)  
Other comprehensive income 3,377       3,377
Exercise of stock options and ESPP share issuance (in shares)   1,219,000      
Exercise of stock options and ESPP share issuance 26,880 $ 12 26,868    
Net proceeds/payments from issuance of common stock (in shares)   5,022,000      
Net proceeds/payments from issuance of common stock 370,978 $ 50 370,928    
Issuance of common stock for vesting of RSUs (in shares)   1,000      
Deferred payments for Business Acquisition and Vertuis Bio, Inc. (in shares)   197,000      
Deferred payments for Business Acquisition and Vertuis Bio, Inc. 14,082 $ 2 14,080    
Issuance of common stock upon conversion of convertible notes (in shares)   5,741,000      
Issuance of common stock upon conversion of convertible notes 224,259 $ 57 224,202    
Stock-based compensation expense 25,545   25,545    
Ending balance (in shares) at Sep. 30, 2024   178,847,000      
Ending balance at Sep. 30, 2024 $ 483,415 $ 1,788 4,605,449 (4,124,369) 547
Beginning balance (in shares) at Dec. 31, 2024 179,382,635 179,383,000      
Beginning balance at Dec. 31, 2024 $ 285,379 $ 1,794 4,645,791 (4,359,917) (2,289)
Comprehensive loss:          
Net loss (948,290)     (948,290)  
Other comprehensive income 4,287       4,287
Exercise of stock options and ESPP share issuance (in shares)   4,461,000      
Exercise of stock options and ESPP share issuance 101,082 $ 44 101,038    
Net proceeds/payments from issuance of common stock (in shares)   8,984,000      
Net proceeds/payments from issuance of common stock 823,282 $ 90 823,192    
Issuance of common stock for vesting of RSUs (in shares)   1,172,000      
Issuance of common stock for vesting of RSUs 12 $ 12      
Issuance of common stock upon conversion of convertible notes (in shares)   17,923,000      
Issuance of common stock upon conversion of convertible notes 566,141 $ 179 565,962    
Issuance of common stock for vesting of PSUs (in shares)   660,000      
Issuance of common stock for vesting of PSUs 7 $ 7      
Stock-based compensation expense $ 113,671   113,671    
Ending balance (in shares) at Sep. 30, 2025 212,583,015 212,583,000      
Ending balance at Sep. 30, 2025 $ 945,571 $ 2,126 6,249,654 (5,308,207) 1,998
Beginning balance (in shares) at Jun. 30, 2025   211,111,000      
Beginning balance at Jun. 30, 2025 1,249,735 $ 2,111 6,184,078 (4,938,186) 1,732
Comprehensive loss:          
Net loss (370,021)     (370,021)  
Other comprehensive income 266       266
Exercise of stock options and ESPP share issuance (in shares)   1,454,000      
Exercise of stock options and ESPP share issuance 34,413 $ 14 34,399    
Net proceeds/payments from issuance of common stock (256)   (256)    
Issuance of common stock for vesting of RSUs (in shares)   10,000      
Issuance of common stock for vesting of PSUs (in shares)   8,000      
Issuance of common stock for vesting of PSUs 1 $ 1      
Stock-based compensation expense $ 31,433   31,433    
Ending balance (in shares) at Sep. 30, 2025 212,583,015 212,583,000      
Ending balance at Sep. 30, 2025 $ 945,571 $ 2,126 $ 6,249,654 $ (5,308,207) $ 1,998